Do payers equally value the cost per month of overall survival for metastatic castration resistant prostate cancer within the EU5?

///Do payers equally value the cost per month of overall survival for metastatic castration resistant prostate cancer within the EU5?
Do payers equally value the cost per month of overall survival for metastatic castration resistant prostate cancer within the EU5?2019-01-18T09:18:28+00:00

Project Description

There have been several recent pharma product launches for the treatment of metastatic castration resistant prostate cancer (mCRPC). The aim of this study was to assess the launch price of mCRPC treatments across the EU5 (France, Germany, Italy, Spain, UK) in relation to a standard clinical measure, overall survival (OS), to determine if payers equally value the cost per OS month for mCRPC treatments. Furthermore, the cost per month of additional OS benefit versus comparator was assessed. An analysis of cost/survival for prostate cancer treatments has been previously conducted in the US.

Read our findings here…. (Do payers equally value)